AVEO News
Archived Headlines
- 4 IPOs planned for the week of Mar 8 03/07/10
- AVEO Pharmaceuticals announces terms for $98 million IPO 02/23/10
- Looking back at 2009: global IPO market in transition 12/23/09
- Online advertising company ReachLocal files for a $100 million IPO 12/22/09
- AVEO submits filing for an $86 million IPO 12/16/09
AVEO quiet period ends April 20
AVEO Pharmaceuticals, which is developing a renal cell carcinoma drug similar to blockbuster Avastin, will see its quiet period end on Tuesday, April 20th. On March 11th, the company raised $81 million by offering 9 million shares at $9, below the range of $13-...read more
Four IPOs test investor appetite, post mixed performances this week
All four companies that were slated to go public this week successfully completed their deals, though three priced at the bottom of their proposed ranges and one was forced to cut its deal size by 18%. Two of the four IPOs, Baltic Trading Limited (BALT)...read more
AVEO Pharmaceuticals prices IPO at $9, below the $13-$15 range
AVEO Pharmaceuticals, which is developing a Phase 3 renal cell carcinoma treatment similar to blockbuster Avastin, raised $81 million by selling 9 million shares at $9 after originally filing to raise $98 million by selling 7 million shares at a range of...read more
AVEO Pharmaceuticals pushes back IPO pricing to Thursday
AVEO Pharmaceuticals, which was originally scheduled to set its IPO price tonight after the market close, pushed back its pricing date to Thursday, Mar. 11. The Cambridge, MA-based biotech is developing a Phase 3 trial for its lead candidate tivozanib, an oral ...read more